Thursday Aug 21
New Market Research Report: Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review
Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations.
Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S.
Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. Seeking Indication Expansion as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures Tokyo, Aug 20, 2014 - - Eisai Co., Ltd. announced today that it has submitted applications to regulatory authorities in the U.S. and Europe for the indication ... (more)
Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan
Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor discovered and developed in-house by Eisai.
"Eisai Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Published
The company's major products include Aricept for Alzheimer's treatment, Aciphex for acid reflux, Aloxi anti-nausea medication injection, Belviq diet drug, Dacogen for the treatment of myelodysplastic syndromes, Banzel for adjunctive treatment, Fragmin low molecular weight heparin, Ontak antineoplastic agent, Panretin for the treatment of skin ... (more)
Eisai Supports Earthquake Relief Efforts in Yunnan, China
Tokyo, Aug 7, 2014 - - Eisai expresses its heartfelt sympathies to all those affected by the recent earthquake which occurred in Ludian county of Zhaotong city, Yunnan province, China.
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment
Leading Toward the Submission of Application for Marketing Authorization in Europe Tokyo, July 31, 2014 - - Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency for its in-house developed anticancer agent lenvatinib mesylate in the treatment of ... (more)